CV Therapeutics
Work in HR? Unlock Free Profile
Suggest Edits

Be The First To
Add Photos

Headquarters Palo Alto, CA
Size 500 to 999 Employees
Founded Unknown
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

CV Therapeutics is more interested in Cardio Vascular drug research than fixing up résumés. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). CV Therapeutics won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing additional potential therapies for ailments including heart failure and... More

Working at CV Therapeutics

Posted by employees

Employees are “Very Satisfied”   2 ratings


100% Approve of the CEO   1 ratings

CV Therapeutics CEO, Chief Science Officer, and Chairman Louis G. Lange

Louis G. Lange

CEO, Chief Science Officer, and Chairman

Cardiovascular Therapeutics, or any other molecule that looks promising…

  Current Employee in Palo Alto, CA

Pros: Some very good people here, some interesting compounds in development. Full Review

More CV Therapeutics Ratings & Reviews ( 2)

Salaries in USD  United States Avg. Salary

Director of Business Development, Clinical

3 CV Therapeutics Salaries


Research Associate

2 CV Therapeutics Salaries



2 CV Therapeutics Salaries


= Salary Range

= Anonymous Salary Range

= Avg.

More CV Therapeutics Salaries (22)

CV Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Worked for CV Therapeutics? Contribute to the Community!